In the opening segment of this 6-part HCPLive RX Review, experts reflect on resmetirom’s FDA approval for MASH and clinical challenges to implementing it.
Back
Celebrating 1 Year of Resmetirom, Progress in MASH/MASLD
An expert panel examining updates and unmet needs in the management of metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD).
Celebrating 1 Year of Resmetirom, Progress in MASH/MASLD
Episodes
All
All
In the second segment of this 6-part HCPLive RX Review, experts discuss unmet needs in MASH care, even with resmetirom available as a treatment option.
In the third segment of this 6-part HCPLive RX Review, experts discuss investigational therapies in the MASH pipeline and the use of combination therapy.
In the fourth segment of this 6-part HCPLive RX Review, experts discuss the continued importance of diet and exercise for managing MASH.
In the fifth segment of this 6-part HCPLive RX Review, experts discuss the evolving role of noninvasive testing in MASH care.
In the final segment of this 6-part HCPLive RX Review, experts discuss resmetirom’s significance and what else gives them hope for the future of MASH care.
Advertisement
Advertisement
Trending on HCPLive
1
Brensocatib Patient Selection Evolves 1 Year After FDA Approval
2
The HCPFive: Top News for Healthcare Providers from the Week of 08/16
3
Q&A: Upadacitinib Drives Eyebrow, Eyelash Regrowth with Consistent Safety
4
ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD
5